Combining BRAF with MEK inhibitors shows meaningful clinical efficacy in terms of objective response rates in extracranial melanoma [22] and quite recently, also in intracranial activity with response rates of 44 to 59% in patients with melanoma BM. This evidence concerns the gene BRAF and melanoma.